Experience

Moderna

• United States
• Biotechnology Research
• 700 & Above Employee

• Scientist, Drug Product Development

  • Nov 2020 - May 2023

  Greater Boston • Subject Matter Expert (SME) responsible for early- and late-stage development activities of a therapeutic LNP drug product with novel formulation and route of administration. o Work with cross-functional groups to streamline processes and maintain timelines o Design, coordinate, execute, and document activities of a small team to support material requests, process knowledge, and regulatory filings. • Lead of the Product Definition Group. o Assess and predict the impact… Show more • Subject Matter Expert (SME) responsible for early- and late-stage development activities of a therapeutic LNP drug product with novel formulation and route of administration. o Work with cross-functional groups to streamline processes and maintain timelines o Design, coordinate, execute, and document activities of a small team to support material requests, process knowledge, and regulatory filings. • Lead of the Product Definition Group. o Assess and predict the impact of material specifications, manufacturing variability, and target product profile on final DP presentation. o Design and analyze human factor studies to assess the impact on Product Definition. o Began with studies then moved towards prediction and optimization. • SME of Excipient Stability Project. o Provide TD/DPD perspective to design and evaluation of studies focused on excipient impact to LNP stability. • DPD Representative on Technical Development Publication Committee. o Contributed to creating the TD publication strategy and submission process. o Attend regular meetings to review and approve proposals for publications and presentations. • Support clinical studies as a SME on DP handling, dose preparation, and in-use stability. o Work alongside Clinical Supplies Group, Clinical Operations, and CROs to ensure successful and timely clinical trials. o Draft pharmacy manual sections, ancillary supply memos, and dose preparation worksheets. Show less



CSL

• Australia
• Biotechnology Research
• 700 & Above Employee

• Investigator I

  • Oct 2018 - Oct 2020

  Greater Boston Area • Produced, characterized, and developed next-generation lipid nanoparticles for influenza vaccination. • Assessed of nanoparticle potency by novel cell-based assay. • Tech transferred LNP platform to internal and external groups then served as an SME for scale-up, process development, and troubleshooting. • Trained new employees on laboratory techniques, methods, and data reporting. • Authored technical reports of research and new protocols. • Reviewed external patents for… Show more • Produced, characterized, and developed next-generation lipid nanoparticles for influenza vaccination. • Assessed of nanoparticle potency by novel cell-based assay. • Tech transferred LNP platform to internal and external groups then served as an SME for scale-up, process development, and troubleshooting. • Trained new employees on laboratory techniques, methods, and data reporting. • Authored technical reports of research and new protocols. • Reviewed external patents for developing IP. • Prepared and presented research at R&D forums regarding on-going research, LNP platform development, and analytical techniques. • Conducted meta-analysis of data for trends and lurking variables based on new data and literature reviews to support product development, reporting and the company’s body of knowledge. • Nominated and served on Brand Ambassador committee to promote company values internally and externally. Show less



University of Michigan

• United States
• Higher Education
• 700 & Above Employee

• Ph.D. Graduate Student

  • Sep 2013 - Aug 2018

  Mentor: James J. Moon, Ph.D. • Collaborated with external and internal investigators to produce and characterize peptide and protein loaded nanoparticle vaccines. • Characterized antigen distribution, display, and stability on nanoparticles. • Conducted in vivo studies assessing immunogenicity of vaccine formulations against viral agents. • Analyzed data and proposed future directions for formulation characterization and optimization. • Adapted established methods and commercial products for use in the… Show more • Collaborated with external and internal investigators to produce and characterize peptide and protein loaded nanoparticle vaccines. • Characterized antigen distribution, display, and stability on nanoparticles. • Conducted in vivo studies assessing immunogenicity of vaccine formulations against viral agents. • Analyzed data and proposed future directions for formulation characterization and optimization. • Adapted established methods and commercial products for use in the lab. • Mentored five lab members on methods, use of equipment, experimental design, and analysis. • Managed technician’s contribution to collaborative projects. • Improved awareness, acceptance, and adherence to safety procedures.

• Research Technician

  • Sep 2012 - Sep 2013

  Mentor: Mark S. Cohen, M.D. • Conducted in vitro and in vivo efficacy studies of semi-synthetic small molecule cancer therapeutics. • Conducted mechanistic studies of semi-synthetic small molecules. • Managed lab efficiency by inventorying, organizing, and ordering reagents.



University of Kansas Medical Center

• Higher Education
• 700 & Above Employee

• Research Technician

  • Aug 2011 - Sep 2012

  Kansas City, Kansas • Conducted in vitro and in vivo efficacy studies of semi-synthetic small molecule cancer therapeutics. • Conducted mechanistic studies of semi-synthetic small molecules. • Managed lab efficiency by inventorying, organizing, and ordering reagents.



University of Missouri-Kansas City

• United States
• Higher Education
• 700 & Above Employee

• Undergraduate Researcher

  • Aug 2010 - Jul 2011

  Mentor: Stephen J. King, Ph.D. • Assessed motility of microtubule associated motor protein dynein in association with the activator protein dynactin.

• Undergraduate Researcher

  • Jan 2011 - May 2011

  Mentor: Bi Botti Youan, Ph.D • Prepared and characterized polymeric nanocapsules for breast cancer therapy.